Genentech Company Description
"The few, the proud, the profitable" could be Genentech's motto. One of the world's most successful biotechs (in an industry full of money-losers), the firm has three billion-dollar blockbusters: Rituxan, which fights non-Hodgkin's lymphoma; Avastin, a treatment for colorectal, breast, and lung cancers; and Herceptin for breast cancer. Lung cancer drug Tarceva rounds out the company's oncology portfolio. Genentech's other marketed drugs include age-related macular degeneration treatment Lucentis, human growth hormone Nutropin, cystic fibrosis drug Pulmozyme, and asthma drug Xolair. Swiss drugmaker Roche, which previously owned a majority stake in the firm, took full ownership of Genentech in 2009.
View the Comprehensive Company Description for Genentech
The Company Description provides a historical perspective of Genentech's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Genentech's evolution in the marketplace.
